| abstract |
The invention describes the crystalline form A 4- [7- (6-cyano-5-trifluoromethylpyridin-3-yl) -8-oxo-6-thioxo-5,7-diazaspiro [3.4] oct-5-yl] -2- fluoro-N-methylbenzamide or its hydrate, solvate or solvated hydrate, which exhibits a powder X-ray diffraction (XRPD) structure with characteristic peaks at 2-theta angles of 4.8 ± 0.1 °, 7.1 ± 0.1 ° , 14.2 ± 0.1 °, 16.3 ± 0.1 ° and 20.1 ± 0.1 °, a pharmaceutical composition containing said crystalline form A, and their use for treating prostate cancer in a mammal. |